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AbstrAct 
Introduction: Enterococci have become the third leading cause of nosocomial 
bacteraemia, an infection which is significantly associated with the risk of developing 
infective endocarditis. Linezolid provides high rates of clinical cure and microbiologic 
success in complicated infections due to Enterococcus spp. However, several 
instances of emergence of resistance during linezolid treatment have been reported. 
The aim of this study was evaluate the activity of tigecycline against linezolid-
intermediate (LIE) and linezolid-resistant enterococcus faecalis (LRE) by the time-
kill assay. 
Methods: Five isolates of LRE and two isolates of LIE were used in this study. 
Minimum inhibitory concentration (MIC) was determined by broth dilution following 
the guidelines from the Clinical and Laboratory Standards Institute (CLSI). Time-kill 
assay was employed to access the in vitro response profile of tigecycline.
results: All seven isolates presented MIC of 0.125 μg/mL. Tigecycline activity was 
individually evaluated according to CLSI criteria. This antibiotic showed bactericidal 
activity against three of the five isolates of LRE and bacteriostatic activity against the 
other isolates.
conclusions: Tigecycline presented both bacteriostatic and bactericidal activity 
against tested isolates, which is an important data that must be considered for new 
studies.
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Enterococci have become the third leading cause of nosocomial 
bacteraemia, an infection which is significantly associated with the risk of 
developing infective endocarditis. The enterococci pose a considerable 
therapeutic problem since they display resistance to a wide range 
of antimicrobial agents, including aminoglycosides, penincilins and 
glycopeptides. The problematic treatment of enterococcal infections 
emphasizes the need for evaluation of new effective therapeutic options1. 
A product of these efforts has been the development of linezolid, a 
synthetic antibiotic that was the first commercially available drug from the 
group of oxazolidinones. Linezolid provides high rates of clinical cure and 
microbiologic success in complicated infections due to Enterococcus spp. 
However, several instances of emergence of resistance during linezolid 
treatment have been reported in clinical isolates of enterococci and 
staphylococci2.
In Brazil, bacteria from the genus Enterococcus are responsible for about 
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10% of all nosocomial infections3. The presence 
of linezolid-intermediate enterococci (LIE) and 
linezolid-resistant enterococci (LRE) has been 
described in nosocomial infections over the last 
years4. However, despite these findings, there are 
no available studies on the relationship of LIE and 
LRE with regard to tigecycline. 
The antimicrobial agent tigecycline, the first 
glycylcycline available for clinical use, was licensed 
by the US Food and Drug Administration (FDA) in 
2005. This drug inhibits bacterial protein translation 
by binding to the 30S ribosomal subunit and 
blocking the entry of amino-acyl tRNA molecules 
into the A site of the ribosome, which prevents 
the incorporation of amino acid residues into 
elongating peptide chains. Tigecycline, a derivative 
of minocycline, is not affected by any of the known 
tetracycline resistance determinants. In general, 
tigecycline is considered bacteriostatic; however, 
bactericidal activity has been demonstrated against 
isolates of S. pneumoniae and L. pneumophila5. 
The reaction of these microorganisms in the face 
of new drugs such as tigecycline has been tested 
through classic assays, taking into consideration 
only the bacterial growth response to antimicrobial 
concentrations, as seen in minimum inhibitory 
concentration (MIC) tests. Conversely, the time-kill 
assay has been employed to further assess in vitro 
response profile, accounting not only for different 
antimicrobial concentrations but also for different 
exposure times.
In order to evaluate the time dependence of 
tigecycline activity, we have undertaken time-kill 
experiments against clinical isolates of LIE and 
LRE.
Methods
The present study includes 2 clinical isolates 
of Enterococcus faecalis recovered from different 
patients and characterized as LIE, as well as 
5 isolates characterized as LRE. Isolates were 
collected from different hospitals in the city of Porto 
Alegre, State of Rio Grande do Sul, Brazil, between 
2008 and 2010.
All isolates were characterized as E. faecalis 
according to a previously described biochemical 
key6. 
An additional identification and a susceptibility 
profile were obtained using the Walk-Away 
MicroScan™ system (SIEMENS). Also, the 
susceptibility profile was confirmed with the disc 
diffusion method (Kirby-Bauer), according to 
Clinical and Laboratory Standards Institute (CLSI) 
guidelines, for the following antibiotics: linezolid 
and tigecycline7.
The MIC assay as well as the previous growth 
(until the inoculum reaches the log phase, in order 
to perform in time-kill assay) were conducted using 
freshly prepared (< 12 h old) cation supplemented 
Mueller-Hinton Broth (MHB) (Becton Dickinson & 
Co, Maryland, USA). 
Trypticase Soy Agar (HiMedia Laboratories Ltd, 
Mumbai, India) was used for colony counts during 
the time-kill assay; quality control of media was 
performed using E. faecalis ATCC 29212. 
The antimicrobial agent tigecycline was provided 
by Wyeth Pharmaceuticals (Collegeville, PA). 
MICs were determined by broth macro dilution 
following CLSI  guidelines7. Tubes containing serial 
dilutions of tigecycline, within a range of 0.0312 to 1 
μg.mL-1, were used. The FDA-approved MIC (μg/
mL) susceptibility breakpoints of tigecycline against 
E. faecalis (vancomycin-susceptible isolates 
only) was ≤ 0.25 for susceptible microorganisms 
(source: Tigecycline package insert; Wyeth 
Pharmaceuticals, Philadelphia, PA).
Time-kill assays were performed twice 
independently according to guideline M26-A of the 
CLSI using polypropylene 96-well deep well plates. 
Suspensions were prepared in flasks containing 
50 ml of fresh MHB and inoculated with 10 µl of 
the seven tested organisms in logarithmic growth 
phase, determined through a growth curve from a 
previous experiment (not shown), and then adjusted 
to obtain a final inoculum of 5 x 105 colony-forming 
units (CFU).mL-1.
The time-kill kinetics of tigecycline was tested 
at the MIC (0.125 µg.mL-1) – obtained by broth 
dilution susceptibility testing –, three dilutions 
above the MIC (0.25 µg.mL-1, 0.5 µg.mL-1and 1 
µg.mL-1), and two dilutions below the MIC (0.0625 
µg.mL-1 and 0.0312 µg.mL-1). Viability counts 
were performed after 0, 2, 4, 8, 12, and 24 hours of 
incubation at 35°C. 
Plates were incubated at 35°C for 24 h, and 
colony counts were determined. A growth control 
was included for each isolate tested. We also 
included a quality control strain, as recommended 
by the CLSI7. 
Bactericidal activity was defined as a reduction 
of 99.9% (≥ 3 log10) in the total count of CFU per 
milliliter of the original inoculum. Bacteriostatic 
activity was defined as the maintenance of the 
original inoculum concentration or a reduction of 
less than 99.9% (< 3 log10) in the total count of the 
original inoculum8.
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results
All seven isolates showed a MIC of 0.125 
µg.mL-1 for tigecycline. 
Tigecycline exhibited bacteriostatic activity 
against all the LIE isolates and two of the LRE 
(table 1). A bactericidal activity was found against 
the other 3 isolates of LRE for at least two 
concentrations above the MIC at 12 or at 24 hours 
(figures 1, 2 and 3).
Tigecycline against LIE and LRE by time-kill assay
Table 1: Reduction in log CFU.mL-1 (observed – initial). 
concentrations 
 ( μg.mL-1) 1 0.5 0.25 0.125 0.0625 0.0312 c+
Isolate number 
1 - lIe
2h -0,07 -0,36 -0,30 -0,57 -0,58 -0,34 0,33
4h -1,19 -1,12 -0,66 -0,59 -0,59 -0,13 0,44
8h -1,28 -1,01 -1,21 -0,94 -0,68 0,09 0,44
12h -2,08 -0,28 -0,95 -1,23 -1,35 0,42 0,44
24h -2,26 -2,56 -2,08 -1,28 -1,51 0,44 0,44
2 - LIE
2h -0,98 -1,27 -0,87 -1,06 -1,04 -0,15 -0,09
4h -1,44 -1,48 -1,76 -1,17 -0,66 0,24 0,24
8h -2,16 -2,16 -1,51 -1,40 -0,82 0,15 0,24
12h -2,46 -1,81 -2,46 -1,44 -0,53 0,24 0,24
24h -2,76 -2,06 -2,16 -2,29 0,24 0,24 0,24
3 - LRE
2h -0,86 -1,45 -1,05 -1,08 -1,07 -0,55 -0,09
4h -1,15 -1,29 -1,30 -1,29 -1,05 -0,29 0,32
8h -1,98 -1,57 -1,90 -1,43 -0,56 0,06 0,32
12h * -1,43 -1,45 -1,73 -0,46 0,32 0,32
24h * * -2,08 -1,73 0,32 0,32 0,32
4- lre
2h -0,77 -0,79 -0,79 -0,59 -0,51 -0,24 0,09
4h -1,34 -1,52 -1,29 -0,96 -0,29 0,00 0,30
8h -1,24 -1,92 -1,92 -1,21 -0,21 0,30 0,30
12h -2,70 -2,00 -1,40 -1,59 -0,35 0,30 0,30
24h * * -2,00 -1,32 0,30 0,30 0,30
5 - LRE
2h -0,80 -0,72 -0,60 -0,60 -0,65 -0,61 0,06
4h -0,84 -0,75 -0,80 -0,69 -0,72 -0,31 0,46
8h -1,03 -0,90 -0,86 -0,94 -0,17 0,46 0,46
12h -1,85 -1,59 -1,43 -1,20 0,19 0,46 0,46
24h -2,07 -2,24 -1,70 -1,37 0,46 0,46 0,46
6 - LRE
2h -0,82 -1,11 -1,12 -0,79 -0,97 -0,66 -0,03
4h -1,08 -1,30 -1,14 -1,01 -0,85 -0,37 0,40
8h -1,75 -1,70 -1,45 -1,28 -0,08 0,40 0,40
12h -2,12 -1,90 -1,52 -2,30 0,27 0,40 0,40
24h -2,30 -2,60 -1,42 -1,82 0,40 0,40 0,40
7 - lre
2h
-1,93 -1,59 -1,93 -1,36 -1,08 -0,77 -0,05
4h
-1,86 -1,50 -1,86 -1,36 -1,04 -0,53 0,23
8h
-2,23 -2,10 -1,93 -1,34 -0,57 0,11 0,29
12h * * -2,71 -2,10 -0,01 0,26 0,29
24h * * * -2,71 0,29 0,29 0,29
* represents bactericidal activity (≥ 3 log10 CFU/mL); LIE: linezolid-intermediate Enterococcus; LRE: linezolid-resistant 
Enterococcus. CFU: colony-forming unity.
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Figure 1: Time-kill curves for Linezolid-Resistant isolate number 3 after incubation with tigecycline for a 
24 hours period of time. 
Figure 2: Time-kill curves for Linezolid-Resistant isolate number 4 after incubation with tigecycline for a 24 
hours period of time. 
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Tigecycline against LIE and LRE by time-kill assay
When the mean of the two LIE isolates 
was evaluated, the antimicrobial presented a 
progressive reduction of bacterial growth after 2 
hours at the concentrations of MIC, 2 x MIC, 4 x 
MIC, and 8 x MIC. At the concentration of 0.5 x 
MIC, tigecycline reduced the bacterial presence at 
2, 4, 8 and 12 hours, although a bacterial regrowth 
occurred at 24 hours. At 0.25 x MIC, there was 
reduction only at 2 hours and 12 hours the bacterial 
growth was the same as at growth control. 
As for LRE isolates, similarly to LIE isolates, 
tigecycline showed as in a progressive reduction 
in bacterial growth at concentrations MIC, 2 x MIC, 
4 x MIC and 8 x MIC at the times of 2, 4, 8, 12 and 
24 hours. At the concentrations below MIC, there 
was a reduction only at 2 hours. After this time a 
bacterial regrowth was found. 
dIscussIon
Currently, insufficient data have been published 
on tigecycline against linezolid-intermediate and 
linezolid-resistant E. faecalis. Considering the 
previous data, the tigecycline MIC approved by 
the FDA for E. faecalis is 0.25 µg.mL-1. Our study 
found a MIC lower than FDA breakpoint, showing 
accordance with a study that tested MICs for the 
same drug in different situations. In this study, 
tigecycline MIC performed with freshly prepared 
Mueller-Hinton broth for E. faecalis ranged from 
0.03 to 0.12 µg.mL-19 
The bacteriostatic effect of tigecycline found in 
this study confirmed previous data. However, it is 
necessary to consider that the authors of the above 
mentioned study employed linezolid-resistant 
Enterococcus faecium, a species that presents high 
rates of resistance to antimicrobials in comparison 
with E. faecalis8. 
The bactericidal effect found in our study has 
not yet been reported in literature for LIE and LRE 
isolates. This activity is defined as a reduction of 
99.9% (≥ 3 log10) of the total count of CFU per 
milliliter of the original inoculum. Our results showed 
a complete reduction of the bacterial growth, a fact 
that makes it impossible to calculate the log of 
CFU.ml-1 (figures 1, 2. and 3). That is the reason 
that a number was not shown in Table 1. 
Furthermore, more studies involving LIE 
and LRE against new pharmaceutical drugs are 
necessary, as well as in vivo studies to evaluate 
more precisely the activity of these antimicrobials.
This study has two limitations that must be 
Figure 3: Time-kill curves for Linezolid-Resistant isolate number 7 after incubation with tigecycline for a 24 
hours period of time.
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considered. The first is the small number of isolates 
and the second is the absence of a genetic profile 
analysis.
Therefore, the antimicrobial analysis of this 
study can be considered an important step on the 
overall analysis of tigecycline. Both bactericidal and 
bacteriostatic activity of tigecycline demonstrates 
the importance of this antimicrobial against LIE 
and LRE isolates and must be considered for new 
studies.
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